Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis

PLoS Medicine

Volumn 14, Issue 1, 2017, Pages

  Hoglund, Richard M ^a,b,c   Workman, Lesley ^a,d   Edstein, Michael D ^e   Thanh, Nguyen Xuan ^f   Quang, Nguyen Ngoc ^f   Zongo, Issaka ^g,h   Ouedraogo, Jean Bosco ^g   Borrmann, Steffen ^i,j   Mwai, Leah ^i,k   Nsanzabana, Christian ^a,c   Price, Ric N ^a,c,l   Dahal, Prabin ^a,c   Sambol, Nancy C ^m   Parikh, Sunil ⁿ   Nosten, Francois ^c,o   Ashley, Elizabeth A ^o   Phyo, Aung Pyae ^o   Lwin, Khin Maung ^o   McGready, Rose ^c,o   Day, Nicholas P J ^b,c   Guerin, Philippe J ^a,c   White, Nicholas J ^b,c   Barnes, Karen I ^a,d   Tarning, Joel ^a,b,c   more..

^a Sorbonne Paris Cité   (United Kingdom)

^b MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^f Military Institute of Hygiene and Epidemiology ^*  (Viet Nam)

^g Public Health Research Institute for Health Sciences   (Burkina Faso)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k AFYA RESEARCH AFRICA   (Kenya)

^l MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ YALE UNIVERSITY   (United States)

^o SHOKLO MALARIA RESEARCH UNIT   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ; PIPERAQUINE; ANTIMALARIAL AGENT; QUINOLINE DERIVATIVE;

ARTICLE; BODY WEIGHT; BOOTSTRAPPING; DRUG BIOAVAILABILITY; DRUG TRANSFORMATION; HUMAN; LITERATURE; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; PERFORMANCE; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; PUBLICATION; QT PROLONGATION; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 85011009020     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002212     Document Type: Article

References (64)

1. World Health OrganizationWorld malaria report 2015. Geneva: World Health Organization; 2015.
2. World Health OrganizationGuidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015.
3. White NJ, Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41(7):1413–22. 9210658
4. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis. 2005;41(4):425–32. doi: 10.1086/43201116028147
5. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis. 2004;190(10):1773–82. doi: 10.1086/42501515499533
6. Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002;35(12):1469–76. doi: 10.1086/34464712471565
7. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol. 2004;57(1):93–9. doi: 10.1046/j.1365-2125.2003.01962.x14678346
8. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004;363(9402):18–22. 14723988
9. White NJ, How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008;7:9. doi: 10.1186/1475-2875-7-918186948
10. Bergstrand M, Nosten F, Lwin KM, Karlsson MO, White NJ, Tarning J, Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Sci Transl Med. 2014;6(260):260ra147. doi: 10.1126/scitranslmed.300531125355697
11. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother. 2012;56(3):1571–7. doi: 10.1128/AAC.05877-1122252804
12. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J, Simplified antimalarial therapeutic monitoring: using the day-7 drug level?Trends Parasitol. 2008;24(4):159–63. doi: 10.1016/j.pt.2008.01.00618353727
13. Sigma-Tau. Application for inclusion of dihydroartemisinin plus piperaquine (DHA/PPQ) fixed dose combination tablets in the 17th WHO Model List of Essential Medicines. 2010 Nov 15 [cited 2016 Dec 1]. http://www.who.int/selection_medicines/committees/expert/18/applications/D_Piperaquine.pdf.
14. Beijing Holley-Cotec Pharmaceuticals. DUO-COTECXIN/6T. 2015 [cited 2015 Dec 15]. http://en.holleycotec.com/products_detail/&productId=29.html.
15. Beijing Holley-Cotec Pharmaceuticals. DUO-CORTECXIN/9T. 2015 [cited 2015 Dec 15]. http://en.holleycotec.com/products_detail/&productId=28.html.
16. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–67. doi: 10.1056/NEJMoa080885919641202
17. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411–23. doi: 10.1056/NEJMoa131498125075834
18. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16(3):357–65. doi: 10.1016/S1473-3099(15)00487-926774243
19. WorldWide Antimalarial Resistance Network (WWARN) DP Study GroupThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10(12):e1001564. doi: 10.1371/journal.pmed.100156424311989
20. Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS ONE. 2010;5(2):e8988. doi: 10.1371/journal.pone.000898820126547
21. Zwang J, Ashley EA, Karema C, D’Alessandro U, Smithuis F, Dorsey G, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE. 2009;4(7):e6358. doi: 10.1371/journal.pone.000635819649267
22. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008;52(3):1052–61. doi: 10.1128/AAC.00955-0718180343
23. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004;57(3):253–62. doi: 10.1046/j.1365-2125.2003.02004.x14998421
24. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91(3):497–505. doi: 10.1038/clpt.2011.25422258469
25. Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58(4):2052–8. doi: 10.1128/AAC.02318-1324449770
26. Sim IK, Davis TM, Ilett KF, Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother. 2005;49(6):2407–11. doi: 10.1128/AAC.49.6.2407-2411.200515917540
27. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NPJ, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56(4):1997–2007. doi: 10.1128/AAC.05756-1122252822
28. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo-Benito J, et al. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J. 2012;11(1):303.
29. Hoglund RM, Adam I, Hanpithakpong W, Ashton M, Lindegardh N, Day NPJ, et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J. 2012;11:398. doi: 10.1186/1475-2875-11-39823190801
30. Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, et al. Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria. Clin Pharmacol Ther. 2015;98(1):87–95. doi: 10.1002/cpt.10425732044
31. Hai TN, Hietala SF, Van Huong N, Ashton M, The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 2008;107(2):145–9. doi: 10.1016/j.actatropica.2008.05.01318585670
32. Annerberg A, Lwin KM, Lindegardh N, Khrutsawadchai S, Ashley E, Day NPJ, et al. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother. 2011;55(9):3971–6. doi: 10.1128/AAC.00279-1121709087
33. Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52(1):237–43. doi: 10.1128/AAC.00555-0717967917
34. Riley RD, Lambert PC, Abo-Zaid G, Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c22120139215
35. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother. 2007;51(11):4090–7. doi: 10.1128/AAC.00486-0717846129
36. WorldWide Antimalarial Resistance Network. The WWARN project terms of submission. 2013 Jun [cited 2015 Sep 19]. http://www.wwarn.org/sites/default/files/attachments/documents/TermsOfSubmission.pdf.
37. WorldWide Antimalarial Resistance Network. Data management and statistical analysis plan (DMSAP) version 1.0. Pharmacology module. 2011 Jun 23 [cited 2016 Dec 1]. http://www.wwarn.org/sites/default/files/PharmacologyDMSAP.pdf.
38. WorldWide Antimalarial Resistance Network. Clinical module: data management and statistical analysis plan version 1.2. 2012 May 25 [cited 2016 Dec 1]. http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf.
39. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE. 2011;6(11):e26005. doi: 10.1371/journal.pone.002600522102856
40. Nguyen TC, Nguyen NQ, Nguyen XT, Bui D, Travers T, Edstein MD, Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg. 2008;79(4):620–3. 18840754
41. Chinh NT, Quang NN, Thanh NX, Dai B, Geue JP, Addison RS, et al. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother. 2009;53(2):828–31. doi: 10.1128/AAC.00927-0819047656
42. Nguyen DVH, Nguyen QP, Nguyen ND, Le TTT, Nguyen TD, Dinh DN, et al. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother. 2009;53(8):3534–7. doi: 10.1128/AAC.01717-0819528277
43. Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (CoarsucamTM) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J. 2012;11:217. doi: 10.1186/1475-2875-11-21722741618
44. Adam I, Tarning J, Lindegardh N, Mahgoub H, McGready R, Nosten F, Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2012;87(1):35–40. doi: 10.4269/ajtmh.2012.11-041022764289
45. Beal SL, Sheiner LB, Boeckmann AJ, NONMEM users guides. San Francisco: NONMEM Project Group, University of California San Francisco; 1992.
46. Beal SL, Sheiner LB, Estimating population kinetics. Crit Rev Biomed Eng. 1982;8(3):195–222. 6754254
47. Lindbom L, Ribbing J, Jonsson EN, Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85–94. doi: 10.1016/j.cmpb.2003.11.00315212851
48. Jonsson EN, Karlsson MO, Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64. 10195646
49. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR, Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72–9. doi: 10.1016/j.cmpb.2010.04.01820627442
50. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66(7):705–12. doi: 10.1007/s00228-010-0804-720300743
51. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO, Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51. doi: 10.1208/s12248-011-9255-z21302010
52. Savic RM, Karlsson MO, Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558–69. doi: 10.1208/s12248-009-9133-019649712
53. Saunders DL, Vanachayangkul P, Lon C, Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014;371(5):484–5. doi: 10.1056/NEJMc140300725075853
54. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59(8):4719–26. doi: 10.1128/AAC.00835-1526014949
55. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15(6):683–91. doi: 10.1016/S1473-3099(15)70049-625877962
56. Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, et al. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:66. doi: 10.1186/s12916-015-0301-z25888957
57. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis. 2015;15(6):692–702. doi: 10.1016/S1473-3099(15)70024-125788162
58. Tarning J, Thana P, Phyo AP, Lwin KM, Hanpithakpong W, Ashley EA, et al. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand. CPT Pharmacometrics Syst Pharmacol. 2014;3:e132. doi: 10.1038/psp.2014.2925163024
59. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, Siba PM, et al. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56(6):3288–97. doi: 10.1128/AAC.06232-1122470119
60. Roshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton M, Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol. 2006;62(5):335–41. doi: 10.1007/s00228-005-0084-916570188
61. Anderson BJ, Holford NHG, Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36. 19252334
62. Johnson TN, Tucker GT, Rostami-Hodjegan A, Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther. 2008;83(5):670–1. doi: 10.1038/sj.clpt.610032718043691
63. Anderson BJ, Holford NH, Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32. doi: 10.1146/annurev.pharmtox.48.113006.09470817914927
64. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014;58(10):6056–67. doi: 10.1128/AAC.02667-1425092702